Search | Clinical Trials Finder

Conditions: Major Depressive Disorder, Healthy Controls
Interventions: Ketamine Hydrochloride, Midazolam injection; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions: Ketamine, Midazolam injection, Fentanyl; Drug
Lead sponsor: Brooke Army Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fort Sam Houston, Texas

Conditions: Critical Illness, Sleep, Acute Lung Injury, Acute Respiratory Distress Syndrome
Interventions: Dexmedetomidine, Midazolam and Fentanyl; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 85 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 2
States / cities: Tucson, Arizona

Conditions: Asthma, Allergic
Interventions: Bronchoscopy/BAL, Airway Brushing; Procedure
Lead sponsor: Andrew D. Luster, M.D.,Ph.D.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744 30 mg oral, Midazolam 3 mg oral + GSK1265744 30mg oral, GSK1265744 400 mg (200 nm), GSK1265744 400 mg (1 micro m), GSK1265744 400 mg (5 micro m); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Abuse, Drug
Interventions: Remimazolam, Midazolam, Saline; Drug · Other
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Atopic Dermatitis
Interventions: Caffeine, Metoprolol, Midazolam, Warfarin, Vitamin K, Omeprazole, Rocatinlimab; Dietary Supplement · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 7
States / cities: North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more

Conditions: Wrist Injuries, Postoperative Pain Control
Interventions: 20ml bolus of 0.5% ropivicaine, 10 ml of 0.5% ropivicaine, Midazolam, Fentanyl; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Procedural Sedation, Endoscopy
Interventions: CNS 7056, Midazolam; Drug
Lead sponsor: Paion UK Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 7
States / cities: Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 4 more

Conditions: Allergy
Interventions: Skin Testing; Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Forearm Fracture
Interventions: Lidocaine, Saline; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 17 Years
Enrollment: 89 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Solid Cancers, Non-Hodgkin's Lymphoma
Interventions: Fulvestrant, GDC-0032, Letrozole, Midazolam; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 674 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 27
States / cities: Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more

Conditions: Total Hip Arthroplasty
Interventions: PENG Block, Lidocaine; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Birmingham, Alabama

Conditions: Obesity
Interventions: PF-07081532, Semaglutide; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Volunteers
Interventions: Midazolam injection, Ketamine Injectable Product, MELT-100; Drug
Lead sponsor: Melt Pharmaceuticals; Industry
Eligibility: 55 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Anesthesia, Tooth Extraction
Interventions: Midazolam Hydrochloride, Fentanyl, Ketamine, Propofol injection, Nitrous oxide; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 16 Years and older
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2024
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Sepsis
Interventions: Muscle stimulation with Niveus medical stimulator, measurement of maximal isometric twitch strength, Muscle Biopsy, Muscle Biopsy Medication: Lidocaine, Muscle Biopsy Medication: Versed, Muscle Biopsy Medication: Fentanyl, Blood and Urine Sampling, ineffective muscle stimulation; Device · Procedure · Drug + 1 more
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Conscious Sedation
Interventions: AQUAVAN® (fospropofol disodium) Injection, Midazolam HCI; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 20
States / cities: Huntsville, Alabama • Fresno, California • Jacksonville, Florida + 17 more

Conditions: Colonoscopy, Colonic Polyps
Interventions: AQUAVAN® (fospropofol disodium) Injection, Midazolam HCl; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 20
States / cities: Huntsville, Alabama • Phoenix, Arizona • Atlanta, Georgia + 16 more

Conditions: Lower Back Pain, Lumbar Radiculopathy
Interventions: Virtual reality, Intravenous sedation, Standard care; Device · Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Pain, Hip Arthroscopy
Interventions: Preop PENG block, Placebo block, Ropivacaine 0.5% Injectable Solution, Normal Saline; Procedure · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Atopic Dermatitis
Interventions: Tralokinumab, Caffeine, Warfarin, Omeprazole, Metoprolol, Midazolam Hydrochloride; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Little Rock, Arkansas • Rogers, Arkansas • San Diego, California + 5 more

Conditions: Crohn Disease, Ulcerative Colitis
Interventions: Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 3
States / cities: Cypress, California • Miami Springs, Florida • Durham, North Carolina

Conditions: Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer), CRC (Colorectal Cancer), Advanced Solid Tumors
Interventions: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin, mFOLFIRINOX, GnP, Midazolam; Drug
Lead sponsor: Alterome Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Orlando, Florida • Boston, Massachusetts • St Louis, Missouri + 6 more

Search by objective public record fields.

Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets

Ketamine for Endoscopic Sedation in Outpatient Adult Endoscopy.

Sleep Intervention During Acute Lung Injury

Lung-Resident Memory Th2 Cells in Asthma

A Randomized Study to Assess the Relative Bioavailability of New Formulations of GSK1265744 Long Acting Parental (LAP) in Healthy Adult Subjects

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis

Single Shot Infraclavicular Brachial Plexus Block vs Local Infiltration After Wrist Arthroscopy Surgery

Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy

The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

Hematoma Block as an Adjunct to Procedural Sedation for Forearm Fracture Reduction

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Trial Comparing Impact of PENG Block on Quality of Recovery Compared to No-block for Primary Total Hip Arthroplasty

A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range

Phase 1 Bioavailability Study of MELT-100 (Midazolam and Ketamine Sublingual) and IV Midazolam or Ketamine

Comparison of Two Intravenous Drug Combinations for Ambulatory Oral & Maxillofacial Surgery

Project 4B: Lower Extremity Strength Training in ICU Patients

An Effectiveness and Safety Study of AQUAVAN® Injection (Fospropofol Disodium) for Sedation During Colonoscopy

Study of AQUAVAN® Injection (AQUAVAN; Fospropofol Disodium) for Sedation During Colonoscopy

Virtual Reality as a Substitute for Procedural Sedation During Epidural Steroid Injections

PENG Block for Arthroscopic Hip Surgery

Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4

A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations